Trial Profile
Evaluation of Efficacy and Safety of Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ketamine (Primary) ; Lacosamide (Primary) ; Levetiracetam (Primary) ; Phenobarbital (Primary)
- Indications Status epilepticus
- Focus Therapeutic Use
- 28 Aug 2017 Planned End Date changed from 1 Dec 2018 to 1 Nov 2016.
- 28 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2016.
- 28 Aug 2017 Status changed from active, no longer recruiting to withdrawn prior to enrolment.